Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-HSC (EGFRvIII)
- Development stage
- Preclinical
- Lead developer
- Immugenia
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR-HSC (EGFRvIII) is an experimental hematopoietic stem cell (HSC)-based chimeric antigen receptor (CAR) therapy being developed by Immugenia for the treatment of glioblastoma (GBM). The therapy involves engineering hematopoietic stem cells to express a CAR directed against EGFRvIII (epidermal growth factor receptor variant III), a tumor-specific mutation found in approximately 30-50% of EGFR-amplified glioblastomas. Unlike conventional CAR-T therapies that utilize mature T cells, this platform uses engineered HSCs designed to continuously generate both CAR-T and CAR-NK cells in vivo. This stem cell-based approach aims to provide sustained anti-tumor immunity, improved persistence, and potentially reduced toxicity compared to traditional adoptive cell transfer methods. The program is currently in the discovery stage of development.
- Other names
- EGFRvIII CAR-HSCCAR-Hematopoietic Stem Cell (EGFRvIII)Immugenia-EGFRvIII-CAR cell therapy
02
Targets
EGFRvIII (Epidermal growth factor receptor variant III)
Beyond the preview
Go deeper on CAR-HSC (EGFRvIII).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-HSC (EGFRvIII).